Role of Immunodeficiency in Acinetobacter baumannii Associated Pneumonia in Mice
Acinetobacter baumannii (A. baumannii) has emerged as a significant opportunistic pathogen, particularly in nosocomial settings, and is associated with high mortality rates in critically ill patients. The interaction between A. baumannii infection and the host immune response plays a crucial role in determining the severity and outcome of the infection. This study aimed to explore the role of immunodeficiency in A. baumannii-induced pneumonia, focusing on the immune response and its impact on lung injury and mortality in a murine model.
The study utilized male BALB/c mice, which were randomly divided into four groups: normal immunity control (NIC), normal immunity infection (NIA), immune-compromised control (CIC), and immune-compromised infection (CIA), with 15 mice in each group. Immunodeficiency was induced in the CIC and CIA groups through intraperitoneal injection of cyclophosphamide (CTX), while pneumonia was induced in the NIA and CIA groups via intranasal instillation of A. baumannii solution. Mice were sacrificed at 6 and 24 hours post-infection for specimen collection, and seven-day mortality was assessed.
The results revealed that A. baumannii stimulation led to a sharp increase in neutrophil recruitment in mice with normal immunity (P = 0.030 at 6 hours), but no significant increase was observed in immunocompromised mice (P = 0.092 at 6 hours, P = 0.772 at 24 hours). The polarization of Th cells, indicated by pulmonary interleukin (IL)-4 and interferon (IFN)-γ levels, was significantly depressed in the CIA group compared to the NIA group (IFN-γ: P = 0.003 at 6 hours; P = 0.001 at 24 hours; IL-4: P < 0.001 at 6 hours; P < 0.001 at 24 hours). Additionally, the accumulation of pulmonary conventional dendritic cells (cDCs) was inhibited in immunocompromised mice following A. baumannii infection (P = 0.033). Correspondingly, A. baumannii-associated pneumonia in immunocompromised mice resulted in higher early-stage mortality and more severe histopathological lung damage.
The study also highlighted the impact of A. baumannii on lung impairment and mortality. Histopathological analysis showed that A. baumannii infection caused thickened alveolar walls, inflammatory cell infiltration, alveolar exudates, and edema, with more severe damage observed in immunocompromised mice. The Smith score for lung injury was significantly higher in the CIA group at 24 hours compared to the NIA group (P < 0.001). Lung wet/dry weight ratios, indicative of pulmonary capillary permeability and tissue injury, were also significantly higher in the CIA group at 24 hours (P = 0.007). Seven-day mortality was 100% in the CIA group, with all mice dying within four days, compared to only 40% mortality in the NIA group.
The findings suggest that A. baumannii can impair the immune response in immunocompromised conditions, leading to more severe lung injury and worse outcomes. The reduced immune response in immunocompromised mice was characterized by decreased neutrophil recruitment, inhibited cDC accumulation, and depressed Th cell polarization. These factors collectively contributed to the heightened severity of A. baumannii-induced pneumonia in immunocompromised mice.
The study also discussed the limitations, including the use of standard A. baumannii strains, which may not fully represent clinical multi-drug resistant strains, and the broad immunosuppressive effects of CTX, which made it challenging to isolate the specific effects of immunodeficiency from the drug’s toxicity. Future research is needed to clarify the mechanisms underlying the reduced immune response to A. baumannii in immunocompromised conditions and to explore potential therapeutic strategies.
In conclusion, this study underscores the critical role of the immune system in combating A. baumannii infections. Immunodeficiency significantly exacerbates the severity of A. baumannii-induced pneumonia, leading to more severe lung injury and higher mortality. Understanding the interplay between A. baumannii and the host immune response is essential for developing effective treatments for this challenging pathogen.
doi.org/10.1097/CM9.0000000000001027
Was this helpful?
0 / 0